President Trump signed an executive order to move marijuana from Schedule I to Schedule III, directing federal agencies to expand medical access, speed research, and protect seniors and veterans while keeping recreational use illegal.

President Donald Trump made a decisive move from the Oval Office, signing an executive order to reschedule marijuana from a Schedule I to a Schedule III controlled substance. The action was framed around medical potential rather than recreational acceptance, and it was presented as a way to open safer treatment options for patients. The scene included officials like Health and Human Services Secretary Robert F. Kennedy Jr. and CMS Administrator Dr. Mehmet Oz. Those present emphasized practical steps to help people, not to loosen drug policy across the board.

Trump delivered a straightforward line about the order’s intent: “Today, I’m pleased to announce that I will be signing an executive order to reschedule marijuana from a Schedule I to a Schedule III controlled substance with legitimate medical uses,” and he repeated the warning that rescheduling is not legalization. He doubled down: “I want to emphasize that the order I am about to sign…doesn’t legalize marijuana in any way, shape, or form, and in no way sanctions its use as a recreational drug,” making the administration’s limits clear. That distinction is meant to calm concerns about a sudden shift toward recreational access. The message from the podium was controlled and policy-focused.

The order gives concrete directives to federal agencies, including instructing Attorney General Pam Bondi to fast-track the reclassification process. The Department of Health and Human Services was asked to design research models that use real-world data to study hemp-derived cannabinoid products while staying inside federal rules. CMS was tapped to develop a model to help seniors access CBD options for pain without exposing them to addiction risks. A White House official will work with Congress to ensure legal, safe CBD products reach the market while cracking down on dangerous alternatives.

The administration framed this as a practical fix for seniors and veterans who deal with chronic pain and high prescription costs. For retirees on fixed incomes, the promise of regulated, non-addictive CBD products could reduce out-of-pocket expenses tied to long-term care. From a conservative angle, removing needless barriers to relief while enforcing strong controls makes sense. The approach aims to balance compassion for those who suffer with firm guardrails against misuse.

Medical experts at the event argued the move rests on evidence that cannabis-derived products can help with certain conditions. Dr. Mehmet Oz said, “There’s some clinical evidence that’s showing that CBDs provide relief from common conditions that affect Americans, including cancer symptoms and chronic pain.” That quote was used to underline the administration’s claim that policy should follow evidence, not stigma. Officials promised research and data collection to guide safe, standardized medical use.

Accountability featured repeatedly in official remarks, stressing oversight to prevent exploitation by unscrupulous actors. The administration signaled zero tolerance for schemes that would let profit-driven companies or street dealers undercut patient safety. Enforcement and regulatory clarity were emphasized as non-negotiable parts of the plan. The goal is to give legitimate patients options without creating new public safety problems.

This policy move was presented as consistent with conservative priorities: helping individuals in need while maintaining law and order. Supporters framed it as cutting red tape that has blocked treatment for veterans and others while keeping a firm federal stance against recreational legalization. The administration argued this is not a cultural concession but a targeted policy change aimed at tangible benefits. It’s positioned as common-sense governance rather than ideological surrender.

Rolling out such a program will require careful cooperation between federal agencies and Congress, as the order explicitly calls for legislative and administrative coordination. The administration asked lawmakers to craft statutory and budgetary support for safer cannabinoid products and to back research that produces clear clinical guidance. Without cooperation, speed and scale will be limited, so officials called for pragmatic, bipartisan work rather than partisan showmanship. The emphasis stayed on patient outcomes and measurable results.

Veterans and seniors were repeatedly named as primary beneficiaries, and officials argued that regulated CBD options represent a humane alternative to opioid-based therapies for many chronic conditions. The policy aims to reduce dependence on high-risk medications and to offer cheaper, supervised alternatives for pain management. That pragmatic focus on harm reduction and cost relief is central to the administration’s argument for rescheduling. At the same time, the line that recreational use remains illegal was reiterated to reassure conservative stakeholders.

Moving marijuana to Schedule III, the administration said, opens pathways for research and medical access without endorsing broader legalization. The message was plain: do the right thing for sick Americans, but keep tough oversight to stop misuse. This is an attempt to deliver policy that answers real needs while preserving law and order. The White House framed the order as leadership that prioritizes citizens’ health and safety over political posturing.